KineMed has entered into a multi-year R&D collaboration GlaxoSmithKline (GSK) to develop kinetic biomarkers.
The collaboration will apply KineMed's biomarker discovery platform in therapeutic areas of interest to GSK.
KineMed president and CEO David Fineman said, "The marriage of KineMed's insights into biology with GSK's clinical portfolio marks the start of an exceptional initiative to advance innovative evidence-based medicines."
The R&D collaboration will focus on identifying, optimizing and validating novel biomarkers that would enable informed and timely decision-making in clinical trials of compounds for muscle wasting, fibrosis and metabolic diseases.
KineMed scientific advisory board chief Marc Hellerstein said the company's shared goal with GSK is to identify causal pathways and kinetic signatures that can better inform drug development decisions.
"KineMed's technology, which measures the dynamics of cellular biochemical networks, is focused on developing better metrics of the disease pathology of those disorders and therefore generates competitive advantage in developing effective drugs against them," Hellerstein added.